Oliver Spandow Net Worth

The estimated Net Worth of Oliver J. Spandow is at least $29.7 Thousand dollars as of 18 November 2020. Mr. Spandow owns over 1,500 units of Nephros Inc stock worth over $29,659 and over the last 5 years he sold NEPH stock worth over $0. In addition, he makes $0 as Director at Nephros Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Spandow NEPH stock SEC Form 4 insiders trading

Oliver has made over 2 trades of the Nephros Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,500 units of NEPH stock worth $8,745 on 18 November 2020.

The largest trade he's ever made was buying 1,500 units of Nephros Inc stock on 18 November 2020 worth over $8,745. On average, Oliver trades about 313 units every 45 days since 2019. As of 18 November 2020 he still owns at least 15,734 units of Nephros Inc stock.

You can see the complete history of Mr. Spandow stock trades at the bottom of the page.

Oliver Spandow biography

Oliver Spandow is Director of the company. He is currently the CFO, Executive Vice President and a member of the board of directors of IDOC, LLC, an optometry-based consulting and member service organization. Prior to IDOC, Mr. Spandow spent 15 years with Johnson and Johnson (J&J), including roles as the General Manager of the JNJ Vision Care business in the United Kingdom and Ireland, Vice President of Strategic Accounts and Business Insights at Vistakon (J&J) USA, and Vice President, Finance and CFO of Vistakon (J&J) USA. While at JNJ, in addition to general finance, sales and marketing roles, he was involved with multiple acquisitions, divestment, and licensing deals. Prior to J&J, Mr. Spandow was a Management Consultant with Price Waterhouse. Mr. Spandow holds a B.S. in Finance from the University of Connecticut and an MBA from the Fuqua School of Business, Duke University.

What's Oliver Spandow's mailing address?

Oliver's mailing address filed with the SEC is C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE, NJ, 07079.

Insiders trading at Nephros Inc

Over the last 6 years, insiders at Nephros Inc have traded over $0 worth of Nephros Inc stock and bought 188,822 units worth $443,998 . The most active insiders traders include Capital Lp Wexford Gp Llcda..., Robert R. Jr. Banks, and Andrew Astor. On average, Nephros Inc executives and independent directors trade stock every 70 days with the average trade being worth of $15,834. The most recent stock trade was executed by Arthur H Amron on 28 May 2024, trading 5,000 units of NEPH stock currently worth $11,200.

What does Nephros Inc do?

nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil

Complete history of Mr. Spandow stock trades at Nephros Inc

Nephros Inc executives and stock owners

Nephros Inc executives and other stock owners filed with the SEC include:

• Andrew Astor,
  CEO, CFO, Pres & Director
• Daron G. Evans,
  Chief Exec. Officer of Specialty Renal Products, Inc
• Daniel D'Agostino,
  Chief Financial Officer
• Arthur Amron,
  Independent Director
• Oliver Spandow,
  Director
• Malcom Persen,
  Director
• Alisa Lask,
  Director
• Thomas Gwydir,
  Director
• Andrew Astor,
  President, Chief Executive Officer, Director
• Daron Evans,
  Chief Executive Officer of Specialty Renal Products
• Greg Lucas,
  Pres of Aether Water Systems
• Wesley S. Lobo,
  Chief Commercial Officer
• Shane Sullivan,
  VP of Sales
• Joleen C. Turner,
  VP of Marketing & Bus. Devel.
• Paul A Mieyal,
  Director
• Joseph Michael Harris,
  Director
• Robert R. Jr. Banks,
  President and CEO
• Tom Gwydir,
  Director
• Malcolm C Persen,
  Director
• Capital Lp Wexford Gp Llcda...,
  
• Wesley S. Lobo,
  Chief Marketing Officer
• Judy Krandel,
  Chief Financial Officer